Novo Nordisk Pharmaceutical Industries, LP
Novo Nordisk Pharmaceutical Industries, LP lists 28 GLP-1 packages in the FDA NDC directory, covering liraglutide and semaglutide.
By Sam Reed · Founder and data lead
Novo Nordisk Pharmaceutical Industries, LP appears on 28 GLP-1 packages in the FDA National Drug Code directory, covering liraglutide and semaglutide. The labeler is the firm whose name is on the package. It is not necessarily the manufacturer, and it is never the telehealth programme that sells you the prescription.
The listing
Every package it lists
Source: FDA National Drug Code directory. A listing is a registration, not an FDA endorsement of the product.
Data sources · cited with retrieval dates
- FDA warning lettersPublished compliance actions, updated weekly
- FDA registered outsourcing facilities503B register, with inspection and enforcement status
- FDA National Drug Code directoryLabeler, product and package listings
NADAC figures are pharmacy acquisition costs, not retail prices and not what you will pay. This content is educational and is not medical advice.